EWA vs XBI
iShares MSCI Australia ETF vs SPDR S&P Biotech ETF
- • XBI has the lower expense ratio at 0.35% vs 0.50% for EWA.
- • EWA pays a higher dividend yield (2.86%).
Side-by-side metrics
| Metric | EWA | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.50% | 0.35% |
Dividend yield Trailing 12-month yield. | 2.86% | 0.34% |
AUM Assets under management — bigger funds are typically more liquid. | $1.35B | $8.30B |
YTD return | 15.01% | 12.92% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 1.02 | 1.09 |
P/E ratio | 21.07 | — |
Last price | $29.48 | $133.66 |
Inception | — | — |
Issuer | iShares | State Street |
EWA top holdings
| CBA.AX | Commonwealth Bank of Australia | 14.61% |
| BHP.AX | BHP Group Ltd | 13.71% |
| WBC.AX | Westpac Banking Corp | 6.62% |
| NAB.AX | National Australia Bank Ltd | 6.15% |
| ANZ.AX | ANZ Group Holdings Ltd | 5.55% |
| MQG.AX | Macquarie Group Ltd | 4.28% |
| WES.AX | Wesfarmers Ltd | 4.16% |
| WDS.AX | Woodside Energy Group Ltd | 3.21% |
| RIO.AX | Rio Tinto Ltd | 3.12% |
| GMG.AX | Goodman Group | 3.04% |
XBI top holdings
| APLS | Apellis Pharmaceuticals Inc | 1.87% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.65% |
| TVTX | Travere Therapeutics Inc Ordinary Shares | 1.62% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.44% |
| TWST | Twist Bioscience Corp | 1.42% |
| SMMT | Summit Therapeutics Inc Ordinary Shares | 1.40% |
| ALKS | Alkermes PLC | 1.38% |
| TGTX | TG Therapeutics Inc | 1.37% |
| MDGL | Madrigal Pharmaceuticals Inc | 1.36% |
| BEAM | Beam Therapeutics Inc | 1.32% |
About EWA
EWA (iShares MSCI Australia ETF) is Australian large and mid-cap equities. Managed by iShares, the fund carries $1.4B in assets under management, an expense ratio of 0.50%, a dividend yield of 2.86%. Its largest holding is Commonwealth Bank of Australia (CBA.AX), which represents 14.6% of the portfolio. Real Estate is the fund's largest sector exposure at 5.0%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $8.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.34%. Its largest holding is Apellis Pharmaceuticals Inc (APLS), which represents 1.9% of the portfolio. Financial Services is the fund's largest sector exposure at 0.2%.